Aroa Biosurgery Limited (ASX: ARX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Aroa Biosurgery Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Aroa Biosurgery Limited (ASX: ARX)
Latest News
Small Cap Shares
This ASX small-cap stock could be set to rise 25%
Small Cap Shares
These small cap ASX shares could rise 50% to 65%
Healthcare Shares
Which small cap ASX share is jumping 10% on strong results
Share Fallers
Why Accent, Aroa, Playside, and Premier Investments shares are tumbling today
Small Cap Shares
2 small cap ASX stocks with big price targets
Small Cap Shares
Experts name 2 small cap ASX stocks to buy for big returns
Small Cap Shares
3 small cap ASX stocks that could rise 40% to 100%+
Healthcare Shares
Bell Potter names the best ASX healthcare stocks to buy in FY25
Small Cap Shares
Guess which small cap ASX stock could rise 50% in a 'transformational year'
Healthcare Shares
3 ASX healthcare shares outperforming on quarterly updates
Share Fallers
Why 29Metals, Aroa Biosurgery, Mader, and Netwealth shares are falling
Share Fallers
Why Aroa Biosurgery, Bank of Queensland, Champion Iron, and Terracom shares are falling
Frequently Asked Questions
-
No, Aroa Biosurgery does not pay shareholder dividends at this time.
-
Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.
ARX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Aroa Biosurgery Limited
Aroa Biosurgery Ltd (ASX: ARX) is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.
The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.